Comparative Pharmacology
Head-to-head clinical analysis: CHOLOVUE versus GASTROMARK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOVUE versus GASTROMARK.
CHOLOVUE vs GASTROMARK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Complexes with anions in the gastrointestinal tract to increase fecal elimination of iodipamide, reducing systemic absorption and enhancing gallbladder visualization.
Gastromark (ferumoxsil) is an oral superparamagnetic contrast agent used in MRI. It contains iron oxide particles that create local magnetic field inhomogeneities, reducing T2* signal in the gastrointestinal tract, thereby improving visualization of abdominal organs by darkening the bowel lumen.
100 mg/kg intravenously over 30 minutes every 3-4 weeks.
Orally, 30-60 mL of a 1% suspension (300-600 mg iron) diluted in water or juice, given 12-24 hours prior to MRI examination; may be repeated if necessary.
None Documented
None Documented
Terminal elimination half-life is 6–8 hours in patients with normal renal function; prolonged to 15–20 hours in moderate renal impairment (CrCl 30–50 mL/min) and >24 hours in severe renal failure.
Terminal elimination half-life: 3.1-3.5 hours; clinical context: supports rapid clearance from the body after imaging.
Primarily renal; approximately 70% excreted unchanged in urine within 24 hours, with the remainder eliminated as glucuronide conjugates via biliary/fecal route (20%) and minor metabolic pathways (10%).
Renal: 23-31% as intact compound; fecal: 69-77% via biliary elimination; very little metabolism.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent